Bipartisan Support Emerges for Trump's 'Most-Favored Nation' Drug Price Plan
Similar Articles
Trump Administration Finalizes Drug Pricing Deal with Regeneron
Trump Signs Executive Order to Fast-Track Psychedelic Drug Research
FDA Grants Fast-Track Review to Three Psychedelic Drugs for Mental Health Conditions
House Removes Pesticide Lawsuit Shield From Farm Bill as White House Changes Surgeon General Nominee
Trump Proposes Suspending Federal Gas Tax as Lawmakers Weigh Relief Options
Senator Peter Welch (D-Vt.) has stated he would support President Trump's push for a 'most-favored nation' drug pricing policy. Welch is co-sponsoring a bipartisan bill with Senator Josh Hawley (R-Mo.) intended to prevent drugmakers from charging Americans more than the international average price.
Facts First
- Senator Peter Welch (D-Vt.) will support President Trump's 'most-favored nation' drug price proposal.
- The policy aims to align U.S. drug prices with those paid by other developed nations.
- Welch and Senator Josh Hawley (R-Mo.) are collaborating on a bipartisan bill to cap American drug prices at or below the international average.
- President Trump has secured 'most-favored nation' deals with at least 16 pharmaceutical companies, though the terms are not public.
What Happened
At the Axios Future of Health summit, Senator Peter Welch (D-Vt.) stated he would vote for President Trump's proposed 'most-favored nation' drug pricing policy. The policy aims to bring U.S. drug prices closer to those paid by other developed nations. Separately, Senator Welch is working with Senator Josh Hawley (R-Mo.) on a bipartisan bill designed to prevent drugmakers from charging Americans more than the international average price. Welch has described this bill as a Congressional 'template' for the administration's goal.
Why this Matters to You
If enacted, this policy could lead to lower prescription drug costs for you. The direct goal is to reduce the prices Americans pay for medications to match levels common in other wealthy countries. A bipartisan legislative effort suggests there may be a viable path in Congress to achieve this, which could increase the likelihood of the policy becoming law.
What's Next
The bipartisan bill from Senators Welch and Hawley may provide a legislative vehicle for the administration's objective. The next steps likely involve further development of that bill and potential negotiations between Congress and the White House to align the executive and legislative approaches.